Mounjaro Guide
Mounjaro is Eli Lilly's brand of tirzepatide, a once-weekly shot. Its label covers blood-sugar control in type 2 diabetes from age 10 up, plus fewer major heart events (heart attack, stroke, cardiovascular death) for diabetic adults whose risk of them is high. Weight loss is not on that label: Lilly sells the same molecule for weight as Zepbound, though some doctors still write Mounjaro off-label for it.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
At a Glance
| Generic Name | Tirzepatide |
| Brand Names | Mounjaro |
| FDA Status | FDA-approved for type 2 diabetes in adults (May 2022) and in children 10 and older (December 2025), and to reduce major cardiovascular events in adults with type 2 diabetes at high risk (August 2026). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).[1] |
| Approval Date | May 13, 2022[1] |
How does Mounjaro work?
Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon. The same pathways simultaneously reduce appetite, slow gastric emptying, and appear to act directly on fat cells — producing the highest weight loss rates of any approved medication.[2][3]
Dosing Schedule
Mounjaro uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
What side effects does Mounjaro cause?
Common: nausea (12–18%), diarrhea (13–16%), vomiting (5–9%), constipation (5–7%), decreased appetite, abdominal pain, injection site reactions. Side effects typically improve after the first 4–8 weeks. Serious (rare): pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury.[1][2]
Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].
Clinical Trial Results
In the SURPASS-2 trial, Mounjaro (tirzepatide 15mg) reduced HbA1c by 2.30 percentage points and produced 5.5 kg (about 12 lbs) more weight loss than semaglutide 1mg.[2]
Where can you get Mounjaro?
Sellers in our register that will dispense tirzepatide, or a compounded version of it, after an online consultation — shipped to your door.
altRX
Best for: compounded semaglutide from $89/month at the same price at every dose
Editorial score · methodology
Editorial score · methodology
Wellorithm
Best for: compounded semaglutide at a flat $247 every 28 days, any dose
Editorial score · methodology
Oak
Best for: a choice of compounded injections, oral semaglutide and brand-name GLP-1s from one cash-pay checkout
Editorial score · methodology
DudeMeds
Best for: compounded semaglutide at $175/month, prepaid as a 3-month kit
Editorial score · methodology
Editorial score · methodology
How much does Mounjaro cost?
19 sellers in the register publish a price; the lowest starts at $299 a month, checked October 2026. What each one charges to start, cheapest at the top. Compounded tirzepatide from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[4], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[5]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[6]. What you actually pay moves with your dose and with whatever promotion happens to be running.
| Provider | Starting Price | Link | |
|---|---|---|---|
| Sesame Care | brand | $299/mo + care fee | Visit |
| Noom | brand | $349/mo | Visit |
| Mochi Health | brand | $499/mo + membership | Visit |
| Vital Edge | brand | $835/mo | Visit |
| Synergy Rx | brand | $947/mo | Visit |
| Oak | brand | $1,200/mo | Visit |
| altRX | brand | $1,249/mo | Visit |
| Maximus | brand | $1,249.99/mo | Visit |
| Effecty | brand | $1,300/mo | Visit |
| Pallas Health | brand | $1,349/mo | Visit |
Show all 19 Mounjaro sellersShowing all 19 sellers
| DudeMeds | brand | $1,350/mo | Visit |
| AlyveRx | brand | $1,395/mo | Visit |
| Eve | brand | $1,399/mo | Visit |
| Layla | brand | $1,399/mo | Visit |
| Vytora Health | brand | $1,399/mo | Visit |
| Wellorithm | brand | $1,399/mo, prepaid | Visit |
| SkinnyRx | brand | $1,400/mo | Visit |
| Corsica Health | brand | $1,499/mo | Visit |
| myRocky | brand | $1,509/mo + program fee | Visit |
Mounjaro Head-to-Head Comparisons
Short verdict pages setting Mounjaro against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.
See all drug-vs-drug verdicts.
Mounjaro Patient Questions, Answered
Questions people actually asked about Mounjaro in named subreddits, each answered from the published trial data.
Mounjaro Reference Cards
One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.
Ranked PubMed Studies on Mounjaro
The peer-reviewed studies on Mounjaro and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.
Related Research on Mounjaro
Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.
Frequently Asked Questions
Sources & methodology — as of November 2026
- 1.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 2.SURPASS-2 Trial — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (Frías JP et al.)— New England Journal of Medicine.PMID: 34170647.
- 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
- 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Glossary
The words sellers use, defined. Tap any term.
- Tirzepatide · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism
- GIP receptor · Mechanism
- Dual agonist · Mechanism